| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
|
Am J Cardiol
|
2003
|
5.77
|
|
2
|
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
|
N Engl J Med
|
2012
|
3.15
|
|
3
|
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
|
Am Heart J
|
2008
|
2.26
|
|
4
|
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
|
Am J Cardiol
|
2005
|
2.11
|
|
5
|
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
|
Am Heart J
|
2005
|
1.60
|
|
6
|
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
|
J Clin Lipidol
|
2011
|
1.45
|
|
7
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
|
J Am Coll Cardiol
|
2006
|
1.42
|
|
8
|
Medical management of patients before the incidence of a cardiovascular event.
|
J Clin Lipidol
|
2009
|
1.39
|
|
9
|
Safety considerations with fibrate therapy.
|
Am J Cardiol
|
2006
|
1.33
|
|
10
|
Statin safety: an assessment using an administrative claims database.
|
Am J Cardiol
|
2006
|
1.22
|
|
11
|
Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
|
Am J Cardiol
|
2008
|
1.05
|
|
12
|
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
|
Am J Cardiol
|
2003
|
0.92
|
|
13
|
Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
|
Am J Manag Care
|
2006
|
0.92
|
|
14
|
Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases.
|
J Clin Lipidol
|
2008
|
0.91
|
|
15
|
Safety considerations with gastrointestinally active lipid-lowering drugs.
|
Am J Cardiol
|
2006
|
0.89
|
|
16
|
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
|
Am J Cardiovasc Drugs
|
2010
|
0.86
|
|
17
|
Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose.
|
Nutr J
|
2009
|
0.85
|
|
18
|
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults.
|
Expert Opin Pharmacother
|
2008
|
0.85
|
|
19
|
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.
|
J Clin Lipidol
|
2008
|
0.84
|
|
20
|
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
|
Future Cardiol
|
2015
|
0.83
|
|
21
|
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
|
Am J Cardiol
|
2003
|
0.82
|
|
22
|
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
|
Metab Syndr Relat Disord
|
2012
|
0.82
|
|
23
|
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
|
Atheroscler Suppl
|
2004
|
0.81
|
|
24
|
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
|
Am Heart J
|
2011
|
0.80
|
|
25
|
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
|
Diabetes Care
|
2010
|
0.78
|
|
26
|
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
|
Value Health
|
2008
|
0.77
|
|
27
|
Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys.
|
Am J Cardiol
|
2004
|
0.77
|
|
28
|
Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
|
Am J Manag Care
|
2007
|
0.77
|
|
29
|
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
|
Postgrad Med
|
2015
|
0.76
|
|
30
|
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
|
J Clin Lipidol
|
2012
|
0.76
|
|
31
|
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
|
Int J Cardiol
|
2012
|
0.76
|
|
32
|
A softgel dietary supplement containing esterified plant sterols and stanols improves the blood lipid profile of adults with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled replication study.
|
J Acad Nutr Diet
|
2013
|
0.75
|
|
33
|
Something important is missing in the ACC/AHA cholesterol treatment guidelines.
|
J Am Pharm Assoc (2003)
|
2015
|
0.75
|